Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins

Journal of Surgical Oncology

Volumn 96, Issue 3, 2007, Pages 241-248

  Bao, Sheng Sun ^a,b   Jiang, Huai Wang ^a   Lin, Lin Liu ^a,b   Shou, Liang Gong ^b   Redmond, H Paul ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2 family proteins; Murine melanoma; Taurolidine

Indexed keywords

PROTEIN BCL 2; TAUROLIDINE; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; DRUG DERIVATIVE; PROTEIN BAX; TAURINE; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; INTRAPERITONEAL DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; NICK END LABELING; PATHOLOGY; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; IN SITU NICK-END LABELING; INJECTIONS, INTRAPERITONEAL; MAXIMUM TOLERATED DOSE; MELANOMA; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; TAURINE; THIADIAZINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35449005877     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20827     Document Type: Article

References (35)

1. Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL Jr: Immunotherapy for melanoma. Cancer Control 2002;9:22-30.
2. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Fadeel B, Orrenius S, Zhivotovsky B: Apoptosis in human disease: A new skin for old ceremony? Biochen Biophs Res Common 1999;1266:699-717.
4. Yasuyuki M, Koichi A: Apoptosis of human melanoma cells by a combination of lonidamine and radiation. J Radiat R 2004;45: 189-194.
5. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D: Metastatic melanoma: Chemotherapy. Semin Oncol 2002;29:427-445.
6. Jemal A, Clegg LX, Ward E, et al.: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
7. Kerr JF, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
8. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
9. Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-1911.
10. Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem 2000;69:217-245.
11. Letai A: Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005;115:2648-2655.
12. Im E, Choi Y, Paik K, Suh H, Jin Y, Kim K: Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett 2001;163:83-93.
13. Cheng E, Levine B, Boise L, Thompson C, Hardwick J: Bax-independent inhibition of apoptosis by Bcl-xL. Nature 1996;379: 554-556.
14. Adams J, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
15. Browne MK, Leslie GB, Pfirrmann RW, Brodhage H: The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms. Surg Gynecol Obstet 1977;145:842-846.
16. Traub WH, Leonhard B, Bauer D: Taurolidine: In vitro activity against mutiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphococcu aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy 1993;39:322-330.
17. Staubach KH, Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation. Langenbecks Arch Chir 1997; 382:S26-S30.
18. Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg 1994;81:1054-1056.
19. Willatts SM, Radford S, Leitermann M: Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: A placebo-controlled, double-blind trial. Crit Care Med 1995;23: 1033-1039.
20. Jacobi CA, Wildbrett P, Volk T, Muller JM: Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth and implantation with laparoscopic surgery in a rat model. Surg Endosc 1999;13:1021-1025.
21. Braumann C, Ordemann J, Wildbrett P, Jacobi CA: Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. Clin Exp Metastasis 2000; 18:547-552.
22. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA: Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 2003;20:387-394.
23. Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 2004;54:249-258.
24. Stendel R, Scheurer L, Stoltenburq, ??, Didinger G, Brock M, Mohel H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 2003;23:2309-2314.
25. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D, Taurolidine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 1999;277:C1229-C1238.
26. Wang JH, Redmond HP, Watson RW, Bouchier-Hayes D: Induction of human endothelial cell apoptosis requires both heat shock and oxidative stress responses. Am J Physiol 1997;272: C1543-C1551.
27. Hersey P, Zhang XD: Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 2003;196:9-18.
28. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-3151.
29. Calabresi P, Goulette FA, Darnowski JW: Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001;61:6816-6821.
30. McCourt M, Wang JH, Sookhai S, Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000;7:685-691.
31. Shrayer DP, Lukoff H, King T, Calabresi P: The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 2003;14:295-303.
32. Ballestrero A, Nencioni A: Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing Jurkat cells. Clin Cancer Res 2004;10:1463-1470.
33. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, Jansen B: Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Re 1998;8:197-203.
34. Tomkova H, Fujimoto W, Arata J: Expression of the bcl-2 homologue bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur J Dermatol 1998;8:256-260.
35. Kilian M, Gregor JI, Heukamp I, Braumann C, Guski H, Schimke I, Walz MK, Jacobi CA, Wenger FA: Impact of taurolidine and octreotide on liver metastasis and lipid peroxidation after laparoscopy in chemical induced pancreatic cancer. Invest New Drugs 2005;23:157-164.